Chronic activation of the NF-κB pathway is associated with progressive neurodegeneration in Parkinson's disease (PD). Given the role of neuronal RING finger protein 11 (RNF11) as a negative regulator of the NF-κB pathway, in this report we investigated the function of RNF11 in dopaminergic cells in PD-associated neurodegeneration. We found that RNF11 knockdown in an in vitro model of PD mediated protection against 6-OHDA-induced toxicity. In converse, over-expression of RNF11 enhanced 6-OHDA-induced dopaminergic cell death. Furthermore, by directly manipulating NF-κB signaling, we showed that the observed RNF11-enhanced 6-OHDA toxicity is mediated through inhibition of NF-κB-dependent transcription of TNF-α, antioxidants GSS and SOD1, and anti-apoptotic factor BCL2. Experiments in an in vivo 6-OHDA rat model of PD recapitulated the in vitro results. In vivo targeted RNF11 over-expression in nigral neurons enhanced 6-OHDA toxicity, as evident by increased amphetamine-induced rotations and loss of nigral dopaminergic neurons as compared to controls. This enhanced toxicity was coupled with the downregulation of NF-κB transcribed GSS, SOD1, BCL2, and neurotrophic factor BDNF mRNA levels, in addition to decreased TNF-α mRNA levels in ventral mesenchephalon samples. In converse, knockdown of RNF11 was associated with protective phenotypes and increased expression of above-mentioned NF-κB transcribed genes. Collectively, our in vitro and in vivo data suggest that RNF11-mediated inhibition of NF-κB in dopaminergic cells exaggerates 6-OHDA toxicity by inhibiting neuroprotective responses while loss of RNF11 inhibition on NF-κB activity promotes neuronal survival. The decreased expression of RNF11 in surviving cortical and nigral tissue detected in PD patients, thus implies a compensatory response in the diseased brain to PD-associated insults. In summary, our findings demonstrate that RNF11 in neurons can modulate susceptibility to 6-OHDA toxicity through NF-κB mediated responses. This neuron-specific role of RNF11 in the brain has important implications for targeted therapeutics aimed at preventing neurodegeneration.
Introduction
Parkinson's disease (PD) is a progressive neurological disorder with motor abnormalities as the cardinal clinical symptom (Coelho and Ferreira, 2012; Fahn, 2003) . A pathological hallmark of PD is the degeneration of dopaminergic neurons in the substantia nigra (SN) (Crossman, 1989) , however the underlying disease-causing mechanisms remain to be elucidated. Recently, human clinical imaging, epidemiological studies and genetic associations have highlighted and confirmed a role for neuroinflammation in PD (Chen et al., 2005; Frank-Cannon et al., 2009; Gerhard et al., 2006; Hald and Lotharius, 2005; Hamza et al., 2010; Hirsch et al., 2005; Ton et al., 2006) as well as raise the possibility that chronic inflammatory responses may promote progressive degeneration of dopaminergic neurons.
Inflammatory responses in the central nervous system are primarily mediated by microglia through the activation of NF-κB, a signaling
